AHomocystinuria
First line
Homocystinuria
First line
Betaine (Cystadane) is first-line treatment for classical homocystinuria and for methyltetrahydrofolate reductase deficiency or B12-dependent remethylation defects in children and adults. approved the drug in 1996; AEMPS confirms the indication. Dose: 100 mg/kg/day split into two intakes, titrated to plasma homocysteine below 15 µmol/L. Therapy is lifelong under a metabolic paediatrician and regular plasma amino-acid panels. There is no alternative regimen.
Sources
- FDA: Cystadane (betaine anhydrous) prescribing information (2017)
- J Inherit Metab Dis: Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. (2017)
- J Inherit Metab Dis: Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. (2017)
- AEMPS: Ficha técnica de Cystadane (betaína) (2022)
ICD-10: E72.1 · ICD-11: 5C50.B